Compare Stocks: AMPH, ARQT, TARS, and MOR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$20.91 +3.6%	$19.83	$16.65 ▼ $31.26	$858.42M	0.89	489,251 shs	305,681 shs
ARQT Arcutis Biotherapeutics	$26.19 +1.4%	$26.52	$15.10 ▼ $31.77	$3.25B	1.49	1.51 million shs	1.11 million shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A
TARS Tarsus Pharmaceuticals	$69.20 +0.5%	$62.41	$48.20 ▼ $85.25	$3.02B	0.53	865,133 shs	448,260 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	+3.62%	+0.63%	+7.78%	+23.95%	-31.40%
ARQT Arcutis Biotherapeutics	+1.39%	+3.56%	-5.72%	+22.84%	+67.56%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	0.00%
TARS Tarsus Pharmaceuticals	+0.46%	+6.81%	+20.35%	+10.76%	+31.26%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$20.91 +3.6%	$19.83	$16.65 ▼ $31.26	$858.42M	0.89	489,251 shs	305,681 shs
ARQT Arcutis Biotherapeutics	$26.19 +1.4%	$26.52	$15.10 ▼ $31.77	$3.25B	1.49	1.51 million shs	1.11 million shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A
TARS Tarsus Pharmaceuticals	$69.20 +0.5%	$62.41	$48.20 ▼ $85.25	$3.02B	0.53	865,133 shs	448,260 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	+3.62%	+0.63%	+7.78%	+23.95%	-31.40%
ARQT Arcutis Biotherapeutics	+1.39%	+3.56%	-5.72%	+22.84%	+67.56%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	0.00%
TARS Tarsus Pharmaceuticals	+0.46%	+6.81%	+20.35%	+10.76%	+31.26%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	1.75	Reduce	$22.00	5.21% Upside
ARQT Arcutis Biotherapeutics	2.67	Moderate Buy	$35.57	35.82% Upside
MOR MorphoSys	0.00	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	2.78	Moderate Buy	$90.50	30.78% Upside

Current Analyst Ratings Breakdown

Latest AMPH, ARQT, TARS, and MOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	TARS Tarsus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$97.00 ➝ $100.00
8/7/2026	AMPH Amphastar Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$21.00 ➝ $20.00
8/7/2026	AMPH Amphastar Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$19.00 ➝ $20.00
8/6/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/6/2026	ARQT Arcutis Biotherapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$34.00 ➝ $38.00
8/6/2026	ARQT Arcutis Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$35.00 ➝ $38.00
8/6/2026	ARQT Arcutis Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$36.00 ➝ $40.00
7/31/2026	TARS Tarsus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$100.00 ➝ $98.00
7/21/2026	TARS Tarsus Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$90.00 ➝ $89.00
7/21/2026	AMPH Amphastar Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/17/2026	TARS Tarsus Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$719.89M	1.24	$4.41 per share	4.74	$18.06 per share	1.16
ARQT Arcutis Biotherapeutics	$376.07M	8.75	N/A	N/A	$1.75 per share	14.97
MOR MorphoSys	$238.28M	11.99	N/A	N/A	$0.35 per share	54.17
TARS Tarsus Pharmaceuticals	$451.36M	6.73	N/A	N/A	$7.90 per share	8.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$98.09M	$1.69	12.37	7.49	4.26	10.76%	14.98%	6.96%	N/A
ARQT Arcutis Biotherapeutics	-$16.14M	$0.21	124.72	22.97	N/A	6.15%	15.05%	6.51%	10/27/2026 (Estimated)
MOR MorphoSys	-$205.35M	-$3.48	N/A	N/A	N/A	-226.79%	-694.31%	-22.55%	N/A
TARS Tarsus Pharmaceuticals	-$66.42M	-$1.09	N/A	121.40	N/A	-7.67%	-13.53%	-8.12%	N/A

Latest AMPH, ARQT, TARS, and MOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	AMPH Amphastar Pharmaceuticals	$0.62	$0.91	+$0.29	$0.67	$179.92 million	$183.90 million
8/6/2026	Q2 2026	TARS Tarsus Pharmaceuticals	-$0.1918	-$0.43	-$0.2382	-$0.43	$169.65 million	$173.91 million
8/5/2026	Q2 2026	ARQT Arcutis Biotherapeutics	$0.0551	$0.11	+$0.0549	$0.11	$118.85 million	$129.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.79	2.40	1.71
ARQT Arcutis Biotherapeutics	0.46	2.92	2.67
MOR MorphoSys	4.98	1.38	1.38
TARS Tarsus Pharmaceuticals	0.21	3.20	3.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
ARQT Arcutis Biotherapeutics	N/A
MOR MorphoSys	18.38%
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	29.60%
ARQT Arcutis Biotherapeutics	9.40%
MOR MorphoSys	0.05%
TARS Tarsus Pharmaceuticals	9.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	1,976	42.54 million	29.95 million	Optionable
ARQT Arcutis Biotherapeutics	150	125.69 million	113.88 million	Optionable
MOR MorphoSys	730	150.62 million	150.55 million	Not Optionable
TARS Tarsus Pharmaceuticals	50	43.88 million	39.65 million	Optionable

AMPH, ARQT, TARS, and MOR Headlines

Recent News About These Companies

Tarsus (TARS) Q2 2026 Earnings Call Transcript

August 13 at 5:31 PM | finance.yahoo.com

Wasatch Advisors LP Buys New Holdings in Tarsus Pharmaceuticals, Inc. $TARS

August 13 at 5:21 AM | marketbeat.com

HC Wainwright Issues Negative Estimate for TARS Earnings

August 13 at 1:28 AM | americanbankingnews.com

HC Wainwright Has Bearish Estimate for TARS Q3 Earnings

August 11, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Cuts Stock Position in Tarsus Pharmaceuticals, Inc. $TARS

August 9, 2026 | marketbeat.com

Tarsus Pharmaceuticals, Inc. $TARS Shares Acquired by Bank of America Corp DE

August 9, 2026 | marketbeat.com

Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Assenagon Asset Management S.A.

August 8, 2026 | marketbeat.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Issues Earnings Results

August 7, 2026 | marketbeat.com

Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M

August 7, 2026 | biopharmadive.comB

Tarsus joins Stargardt race to market with $800m Alkeus takeover

August 7, 2026 | finance.yahoo.com

Tarsus Pharmaceuticals Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Tarsus Pharmaceuticals Inc (TARS) (Q2 2026) Earnings Call Highlights: Record XDEMVY Sales and ...

August 6, 2026 | finance.yahoo.com

Tarsus projects $685M-$705M in 2026 XDEMVY net product sales while advancing Alkeus acquisition

August 6, 2026 | seekingalpha.com

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Tarsus Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 6, 2026 | seekingalpha.com

Tarsus pays $450M for Alkeus and its phase 3-stage retinal disease drug

August 6, 2026 | fiercebiotech.comF

Tarsus Pharmaceuticals to buy Alkeus Pharmaceuticals

August 6, 2026 | msn.com

Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition

August 6, 2026 | msn.com

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

August 6, 2026 | zacks.com

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

August 6, 2026 | globenewswire.com

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

August 6, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AMPH, ARQT, TARS, and MOR Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$20.91 +0.73 (+3.62%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$20.93 +0.02 (+0.10%)

As of 08/14/2026 07:34 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Arcutis Biotherapeutics NASDAQ:ARQT

$26.19 +0.36 (+1.39%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$25.83 -0.36 (-1.38%)

As of 08/14/2026 07:59 PM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)

As of 08/13/2026

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Tarsus Pharmaceuticals NASDAQ:TARS

$69.20 +0.32 (+0.46%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$69.24 +0.04 (+0.06%)

As of 08/14/2026 07:34 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMPH, ARQT, TARS, and MOR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMPH, ARQT, TARS, and MOR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMPH, ARQT, TARS, and MOR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AMPH, ARQT, TARS, and MOR Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

Arcutis Biotherapeutics NASDAQ:ARQT

MorphoSys NASDAQ:MOR

Tarsus Pharmaceuticals NASDAQ:TARS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMPH, ARQT, TARS, and MOR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMPH, ARQT, TARS, and MOR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMPH, ARQT, TARS, and MOR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AMPH, ARQT, TARS, and MOR Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

Arcutis Biotherapeutics NASDAQ:ARQT

MorphoSys NASDAQ:MOR

Tarsus Pharmaceuticals NASDAQ:TARS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools